

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
National Cancer Center	05/18/2012
RECEIVING PARTY DATA	
Name:	Chugai Seiyaku Kabushiki Kaisha
Street Address:	5-1, Ukima 5-chome
City:	Kita-ku, Tokyo
State/Country:	JAPAN
Postal Code:	115-8543
Name:	National Cancer Center
Street Address:	1-1, Tsukiji 5-chome
City:	Chuo-ku, Tokyo
State/Country:	JAPAN
Postal Code:	104-0045
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	12996162
CORRESPONDENCE DATA	
Fax Number:	(202)371-2540
Phone:	2023712600
Email:	selmer@skgf.com, dcadieus@skgf.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	Steme, Kessler, Goldstein & Fox P.L.L.C
Address Line 1:	1100 New York Avenue, NW
Address Line 4:	Washington, DISTRICT OF COLUMBIA 20005
ATTORNEY DOCKET NUMBER:	2144.0590000/RWE/SLE

OP \$40.00 12996162

NAME OF SUBMITTER:

Stephanie L. Elmer

Total Attachments: 2

source=21440590000_NCC_TO_CHUGAI_ASGN#page1.tif

source=21440590000_NCC_TO_CHUGAI_ASGN#page2.tif

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration, receipt of which is hereby acknowledged, **National Cancer Center**, a corporation organized and existing under the laws of Japan and having an office and place of business at 1-1, Tsukiji 5-chome, Chuo-ku, Tokyo, JAPAN 104-0045, hereby sells and assigns to **Chugai Seiyaku Kabushiki Kaisha** and **National Cancer Center**, each of which is formed under the laws of Japan and having offices and places of business, respectively, at 5-1, Ukima 5-chome, Kita-ku, Tokyo, JAPAN 115-8543 and 1-1, Tsukiji 5-chome, Chuo-ku, Tokyo, JAPAN 104-0045 (hereinafter referred to as the Assignee), its entire right, title and interest for the United States of America (as defined in 35 U.S.C. § 100), and throughout the world, including the right to sue for past infringement and to collect for all past, present and future damages,

(a) in the invention(s) known as **Neuroinvasion Inhibitor** for which application(s) for patent in the United States of America has a 371(c) date of March 7, 2011 (also known as United States Application No. 12/996,162, which is the U.S. national phase of International Application No. PCT/JP2009/060314, International Filing Date June 5, 2009), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned Assignor agrees to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-

PATENT

REEL: 028536 FRAME: 0290

part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned Assignor agrees to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned Assignor hereby represents that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned Assignor hereby grants the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned Assignor on the date opposite his/her name.

SIGNED on behalf of the said ASSIGNOR,

NATIONAL CANCER CENTER

By: Tomomitsu Hotta
Name: Tomomitsu Hotta
Title: President
Date: May 18, 2012

1360245.1